SCHEMBL803732

SCHEMBL803732

CSc1nccc(N2CCC(N(C)C(=O)OCc3ccccc3)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.45
CCR5 P51681 1/20 0.45
PDE10A Q9Y233 2/20 0.42
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
OGA O60502 2/20 0.39
TMEM97 Q5BJF2 2/20 0.38
HTR1A P08908 1/20 0.38
CHRM5 P08912 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
ADRA1D P25100 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL803772 0.87 SIGMAR1 (0.47) SIGMAR1CCR5PDE10AOGATMEM97
SCHEMBL803806 0.85 SIGMAR1 (0.46) SIGMAR1CCR5PDE10AOGATMEM97
SCHEMBL803974 0.85 SIGMAR1 (0.45) SIGMAR1CCR5PDE10AOGATMEM97
SCHEMBL803481 0.85 SIGMAR1 (0.50) SIGMAR1CCR5PDE10ATMEM97HTR1A
SCHEMBL803724 0.84 CCR5 (0.47) SIGMAR1CCR5PDE10AOGATMEM97
SCHEMBL20544017 0.82 MAPT (0.49) PDE10AALDH1A1LMNAGAAMAPT
SCHEMBL16855357 0.81 PDE10A (0.49) PDE10AALDH1A1LMNAGAAMAPT
SCHEMBL16855474 0.78 ALDH1A1 (0.40) PDE10AALDH1A1LMNAGAAMAPT
Hydrochloric Acid SCHEMBL18166971 0.77 ALDH1A1 (0.39) PDE10AALDH1A1LMNAGAAMAPT
Hydrochloric Acid SCHEMBL18166972 0.77 ALDH1A1 (0.39) PDE10AALDH1A1LMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 SIGMAR1 369/4885CCR5 460/4885PDE10A 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.